Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma

British Journal of Radiology

Volumn 82, Issue 982, 2009, Pages 860-876

  Wong, Ka Kit ^a   Zarzhevsky, N ^a   Cahill, J M ^a   Frey, K A ^a   Avram, A M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; RECOMBINANT THYROTROPIN; SODIUM IODIDE SYMPORTER; THYROGLOBULIN;

CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; GLUCOSE METABOLISM; HUMAN; IMAGE DISPLAY; MEDICAL DECISION MAKING; POSTOPERATIVE PERIOD; RECURRENT CANCER; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CARCINOMA; THYROID INCIDENTALOMA; THYROID SCINTISCANNING; THYROIDECTOMY;

ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SYMPORTERS; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 70349269866     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/25645894     Document Type: Review

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. Ca Cancer J Clin 2008;58:71-96.
2. Jonklaas J, Sarlis NJ, LitofskyD,Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:1229-1242 (Pubitemid 46080167)
3. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-142
4. British Thyroid Association, Royal College Of Physicians. Guidelines For the management of thyroid cancer (2nd edn). 2007. Available from: http://www.british-thyroid-association.org/Guidelines/ [Accessed 24 March 2009].
5. Hay ID, Mcconahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 2002;113:241-260
6. Hay ID, Mcdougall IR, Sisson JC. Perspective: the case against radioiodine remnant ablation in patients with well-differentiated thyroid carcinoma. J Nucl Med 2008;49:1395-1397
7. Buck AK, Nekolla S, Ziegler S, Beer A, Krause BJ, Herrmann K, et al. SPECT/CT. J Nucl Med 2008;49:1305-1319
8. Tharp K, Israel O, Hausmann J, Bettman L, Martin WH, Daitzchman M, et al. Impact of I-131 SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging 2004;31:1435-1442 (Pubitemid 39361941)
9. Wong K, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. The value of diagnostic 131-I SPECT-CT fusion imaging in the evaluation of differentiated thyroid carcinoma. AJR Am J Roentgenol 2008;191:1785-1794
10. Shapiro B, Rufini V, Jarwan A, Geatti O, Kearfott KJ, Fig LM, et al. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med 2000;30:115-132 (Pubitemid 30211275)
11. Haveman JW, Phan HT, Links TP, Jager PL, Plukker JT. Implications of mediastinal uptake of 131I with regard to surgery in patients with differentiated thyroid carcinoma. Cancer 2005;103:59-67.
12. Feine U. Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer. Eur J Endocrinol 1998;138:492-496
13. Lind P, Kohlfurst S. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med 2006;36:194-205. (Pubitemid 43817844)
14. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:91-95 (Pubitemid 38183865)
15. Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006;47:616-624 (Pubitemid 46768462)
16. Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med 2004;34:122-133 (Pubitemid 38375467)
17. Cohade C, Osman M, Pannu HK, Wahl RL. Uptake in supraclavicular area fat ("usa-fat"): description on 18f-FDG PET/CT. J Nucl Med 2003;44:170-176
18. Are C, Hsu JF, Schoder H, Shah JP, Larson SM, Shaha AR. FDG-PET detected thyroid incidentalomas: need for further investigation? Ann Surg Oncol 2007;14:239-247
19. Choi JY, Lee KS, Kim HJ, Shim YM, Kwon OJ, Park K, et al. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: Clinical significance and improved characterization. J Nucl Med 2006;47:609-615 (Pubitemid 46772890)
20. Kang KW, Kim SK, Kang HS, Lee ES, Sim JS, Lee IG, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F- fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003;88:4100-4104
21. Chu QD, Connor MS, Lilien DL, Johnson LW, Turnage RH, Li BD. Positron emission tomography (PET) positive thyroid incidentaloma: the risk of malignancy observed in a tertiary referral center. Am Surg 2006;72:272-275
22. Van Den Bruel A, Maes A, De Potter T, Mortelmans L, Drijkoningen M, Van Damme B, et al. Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab 2002;87:1517-1520 (Pubitemid 34615231)
23. De Geus-Oei LF, Pieters GF, Bonenkamp JJ, Mudde AH, Bleeker-Rovers CP, Corstens FH, et al. 18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med 2006;47:770-775 (Pubitemid 46768439)